Document is current

Documents that mention this clinical trial

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
https://doi.org/10.1136/rmdopen-2018-000749

THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217

SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
https://doi.org/10.1136/annrheumdis-2018-eular.4474

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
https://doi.org/10.1136/annrheumdis-2016-210023

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
https://doi.org/10.1136/annrheumdis-2016-209730

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
https://doi.org/10.1136/bmjopen-2020-039059

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
https://doi.org/10.1007/s40744-020-00269-6

FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
https://doi.org/10.1136/rmdopen-2019-001005

SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
https://doi.org/10.1136/annrheumdis-2018-eular.1899

THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials
https://doi.org/10.1136/annrheumdis-2017-eular.4894

SAT0315 STRUCTURAL DAMAGE PROGRESSION OVER 4 YEARS OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: POST-HOC ANALYSIS OF MEASURE-1 TRIAL USING A LONGITUDINAL BAYESIAN MIXTURE MODEL
https://doi.org/10.1136/annrheumdis-2019-eular.4534

Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis
https://doi.org/10.1136/rmdopen-2023-003468

Documents that mention this clinical trial

THU0397 Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from a phase 3 extension trial (MEASURE 1)
https://doi.org/10.1136/annrheumdis-2017-eular.1195

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
https://doi.org/10.1007/s40744-020-00269-6

SAT0268 Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.1396

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
https://doi.org/10.1136/rmdopen-2019-001005

FRI0386 RELATIONSHIP BETWEEN ASDAS STATES AND INHIBITION OF STRUCTURAL DAMAGE PROGRESSION WITH SECUKINUMAB IN ANKYLOSING SPONDYLITIS: DATA FROM MEASURE 1 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.1255

Documents that mention this clinical trial

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
https://doi.org/10.1136/rmdopen-2018-000749

THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2217

SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis
https://doi.org/10.1136/annrheumdis-2018-eular.4474

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
https://doi.org/10.1136/annrheumdis-2016-210023

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
https://doi.org/10.1136/bmjopen-2020-039059

POS0937 MEASURE 2: SECUKINUMAB PROVIDES RAPID AND SUSTAINED RELIEF FROM KEY CLINICAL SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN TNFi-NAÏVE PATIENTS THROUGH 5 YEARS
https://doi.org/10.1136/annrheumdis-2022-eular.2049

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
https://doi.org/10.1007/s40744-020-00269-6

SAT0283 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the phase iii trial, measure 2
https://doi.org/10.1136/annrheumdis-2018-eular.3703

THU0369 Secukinumab 150mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from phase iii trial, measure 2
https://doi.org/10.1136/annrheumdis-2017-eular.1295

FRI0271 IMPACT OF HLA-B27 STATUS ON CLINICAL OUTCOMES AMONG PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1448

A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis
https://doi.org/10.1007/s40744-021-00380-2

FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL
https://doi.org/10.1136/annrheumdis-2019-eular.5531

THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials
https://doi.org/10.1136/annrheumdis-2017-eular.4894

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2
https://doi.org/10.1136/rmdopen-2017-000592